AFP and neoplasm: In the high-tumor-marker group divided by post-treatment AFP levels (>10 ng/mL), the median AFP levels significantly decreased from 15.3 ng/mL to 1.3 ng/mL after treatment (p = 0.002), while PIVKA-II levels showed no significant change (p = 0.307).